Comparison of efficacy of a single daily dose of 400 mg acebutolol and 100 mg atenolol in the treatment of arterial hypertension

References

• Ashton W. L. Acebutolol (400 mg) given as a single daily dose to hypertensive patients previously stabilized on 400 mg acebutolol daily in divided doses: an open multicentre study. Br. J. Clin. Pharmarol. 1978; 9: 209–2121. Ashton W. L. Acebutolol (400 mg) given as a single daily dose to hypertensive patients previously stabilized on 400 mg acebutolol daily in divided doses: an open multicentre study. Br. J. Clin. Pharmarol. 1978; 9: 209–212
   Google Scholar
• Basil B., Jordan R. The metabolism of acebutolol. Nouv. Presse Méd. 1978; 7: 32582. Basil B., Jordan R. The metabolism of acebutolol. Nouv. Presse Méd. 1978; 7: 3258
   PubMedGoogle Scholar
• Basil B., Jordon R., Loveless A. H., Maxwell D. R. Beta-adrenoceptor blocking properties and cardioselectivity of M&B 17,803A. Br. J. Clin. Pharmacol. 1973; 48: 198–2113. Basil B., Jordon R., Loveless A. H., Maxwell D. R. Beta-adrenoceptor blocking properties and cardioselectivity of M&B 17,803A. Br. J. Clin. Pharmacol. 1973; 48: 198–211
   Web of Science ®Google Scholar
• Coombs T. J., Coulson C. J., Smith V. J. Blood plasma binding of acebutolol and diacetolol in man. Br. J. Clin. Pharmacol. 1980; 9: 395–3974. Coombs T. J., Coulson C. J., Smith V. J. Blood plasma binding of acebutolol and diacetolol in man. Br. J. Clin. Pharmacol. 1980; 9: 395–397
   PubMed Web of Science ®Google Scholar
• Fitzgerald J. D., Ruffin R., Smedstad K. G., Roberts R., McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eu, J. Clin. Pharmacol. 1978; 13: 81–895. Fitzgerald J. D., Ruffin R., Smedstad K. G., Roberts R., McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eu, J. Clin. Pharmacol. 1978; 13: 81–89
   PubMed Web of Science ®Google Scholar
• Gulaid A. A., James I. M., Kaye C. M., Lewellen O. R. W., Roberts E., Sankey M., Smith J., Templeton R., Thomas R. J. The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b. d.). Biopharm. Drug Disposit. 1981; 2: 103–1146. Gulaid A. A., James I. M., Kaye C. M., Lewellen O. R. W., Roberts E., Sankey M., Smith J., Templeton R., Thomas R. J. The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b. d.). Biopharm. Drug Disposit. 1981; 2: 103–114
   PubMed Web of Science ®Google Scholar
• Harms H. H. Cardioselectivity of beta-adrenoceptor blocking agents: in vitro studies with human and guinea pig preparations. Beta-adrenoceptor Blocking Agents, P. R. Saxena, R. P. Forsyth. North Holland, Amsterdam 1976; 311–3157. Harms H. H. Cardioselectivity of beta-adrenoceptor blocking agents: in vitro studies with human and guinea pig preparations. Beta-adrenoceptor Blocking Agents, P. R. Saxena, R. P. Forsyth. North Holland, Amsterdam 1976; 311–315
   Google Scholar
• Harms H. H., Spoelstra A. J. G. Cardiac and bronchial beta-adrenoceptor antagonistic potencies of atenolol, metoprolol, acebutolol, practolol, propranolol and pindolol in the anaesthetized dog. Clin. Exp. Pharmacol. Physiol. 1978; 5: 53–598. Harms H. H., Spoelstra A. J. G. Cardiac and bronchial beta-adrenoceptor antagonistic potencies of atenolol, metoprolol, acebutolol, practolol, propranolol and pindolol in the anaesthetized dog. Clin. Exp. Pharmacol. Physiol. 1978; 5: 53–59
   PubMed Web of Science ®Google Scholar
• Jack D. B. Is there a relationship between the physical properties and cardioselectivity of beta-adrenoceptor antagonists. Br. J. Clin. Pharmocol. 1981; 11: 402–4069. Jack D. B. Is there a relationship between the physical properties and cardioselectivity of beta-adrenoceptor antagonists. Br. J. Clin. Pharmocol. 1981; 11: 402–406
   PubMed Web of Science ®Google Scholar
• Marshall A. J., Barritt D. W., Harry J. D. Dose response and frequency of administration of atenolol in essential hypertension — once daily treatment with beta-blockade. Postgrad. Med. J. 1977; 53: 168–172, Suppl. 310. Marshall A. J., Barritt D. W., Harry J. D. Dose response and frequency of administration of atenolol in essential hypertension — once daily treatment with beta-blockade. Postgrad. Med. J. 1977; 53: 168–172, Suppl. 3
   PubMed Web of Science ®Google Scholar
• Ohashi K., Warrington S. J., Kaye C. M., Houghton G. W., Dennis M., Templeton R., Turner P. Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol. Br. J. Clin. Pharmacol. 1981; 12: 561–56511. Ohashi K., Warrington S. J., Kaye C. M., Houghton G. W., Dennis M., Templeton R., Turner P. Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol. Br. J. Clin. Pharmacol. 1981; 12: 561–565
   PubMed Web of Science ®Google Scholar
• Turner A. S., Watson O. E, Brocklehurst J. C. Efficacy of atenolol and oxprenolol in the treatment of arterial hypertension. Med. J. Aust. 1979; 1: 625–62612. Turner A. S., Watson O. E, Brocklehurst J. C. Efficacy of atenolol and oxprenolol in the treatment of arterial hypertension. Med. J. Aust. 1979; 1: 625–626
   PubMed Web of Science ®Google Scholar
• Watson R. D. S., Stallard T. J., Littler W. A. Comparison of once and twice daily administration of acebutolol in hypertension. Br. J. Clin. Pharmacol. 1980; 9: 209–21213. Watson R. D. S., Stallard T. J., Littler W. A. Comparison of once and twice daily administration of acebutolol in hypertension. Br. J. Clin. Pharmacol. 1980; 9: 209–212
   PubMed Web of Science ®Google Scholar
• Winkle R. A., Meffin P. J., Ricks W. B., Harrison D. C. Acebutolol metabolite plasma concentration during chronic oral therapy. Br. J. Clin. Pharmacol. 1977; 4: 519–52214. Winkle R. A., Meffin P. J., Ricks W. B., Harrison D. C. Acebutolol metabolite plasma concentration during chronic oral therapy. Br. J. Clin. Pharmacol. 1977; 4: 519–522
   PubMed Web of Science ®Google Scholar
• Zaman R., Jack D. B., Kendall M. J. The penetration of acebutolol and its major metabolite, diacetolol, into human cerebrospinal fluid and saliva. Br. J. Clin. Phormacol. 1981; 12: 427–42915. Zaman R., Jack D. B., Kendall M. J. The penetration of acebutolol and its major metabolite, diacetolol, into human cerebrospinal fluid and saliva. Br. J. Clin. Phormacol. 1981; 12: 427–429
   PubMed Web of Science ®Google Scholar